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Aryl isoselenocyanates 1 react with different phenacyl halides 2 in the presence of 
hydrazine hydrate in a one-pot reaction to give selenadiazines 3a-f in good to excellent 
yields.  
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1. Introduction. – Selenium-containing heterocycles are of remarkable interest 
because of their antitumor, antibacterial and other notable biological and pharmaceutical 
activities [1]. Among our efforts devoted to the chemistry of selenium in organic synthesis, 
we were also interested in the preparation of selenadiazines. Several articles deal with the 
synthesis of 1,3,4- [2–4], 1,3,5- [5][6], and 1,2,6-selenadiazines [7] but, to the best of our 
knowledge, no synthesis has been described starting from isoselenocyanates. Some 
selenadiazines are of biological and physical interest and are found to be cardiotonic [8] or 
spasmolytic agents [9], but they are also of importance as agrochemicals, dyes and organic 
electric conductors [10].  
In numerous articles, the synthesis of 1,3,4-selenadiazine derivatives by ring enlargement 
of other selenium-containing heterocycles like selenadiazoles or selenazoles is described 
[11][12]. However, most of the papers showed the uses of the selenoureas [13], 
selenosemicarbazides [14][15] or phenyl acetylene selenide as intermediates [16]. 
As a part of our program aimed at the development of simple new procedures for the 
synthesis of selenium-containing heterocycles [17–24], we have recently reported on the 
utility of isoselenocyanates as building blocks for the synthesis of 1,3-selenazetidines [25], 
1,3-selenazolidines and perhydro-1,3-selenazines [26], 2-methylidene-1,3-selenazolidine 
derivatives [27], and 1,3-selenazepanes [28]. As an extension of this work, we report here 
on a novel and efficient synthesis of 1,3,4-selenadiazines. 
 
2. Results and Discussion. – The used isoselenocyanates 1a–1e (see Tab. 1) have 
been prepared conveniently by a slightly modified procedure of Barton et al. [29] from the 
corresponding N-arylformamide by treatment with COCl2 and elemental Se. Then, 
hydrazine hydrate was added to a mixture of equimolar amounts of 1 and a phenacyl halide 
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2 in CH2Cl2 at room temperature. After stirring for 3–4 h, the reaction was complete (TLC) 
and the solvent was evaporated. The product was purified by column chromatography on 
silica gel using a mixture of hexane and AcOEt (ratio from 1/0 to 1/1) and recrystallized 
from AcOEt. The IR-spectra (KBr) of the pale-yellow solids showed two characteristic 
strong absorptions at ca. 1590 and 1560 cm-1 but no C=O absorption. The NMR-spectra 
revealed the presence of an NH (11.3–11.8 ppm) and a CH2 group (3.8–3.95 (1H) and ca. 
15 ppm (13C)), and the CI-MS and elemental analyses were in accordance with the structure 
of a 3,6-dihydro-2-imino-2H-1,3,4-selenadiazine 3 or its 2-amino tautomer (Scheme 1). 
Finally, the structure of 3a was established by X-ray crystallography (Figure). 
 
Scheme 1 
 
Figure. ORTEP Plot [30] of the molecular structure of 3a (arbitrary numbering of the 
atoms, 50% probability ellipsoids) 
 
In the heterocyclic ring, the unsubstituted C-atom is a CH2 group, and only one ring 
N-atom carries an H-atom. The other one is involved in a C=N bond.  The heterocyclic ring 
has a distorted boat conformation. The NH group forms an intermolecular H-bond with the 
exocyclic imine N-atom of a neighboring molecule. In turn, the acceptor molecule makes 
an identical H-bond to the original molecule so that pairs of molecules are linked into 
centrosymmetric dimeric units. The H-bonding can be described by a graph set motif [31] 
of R2,2(8). 
The described one-pot reaction of 1, 2, and hydrazine led to the products 3a–3f in 55–
80% yield (Table 1). Several attempts have been made to carry out this three-component 
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reaction in two consecutive steps. The treatment of 1 with hydrazine hydrate, followed by 
the addition of a phenacyl halide 2, did not yield the desired product, but the corresponding 
selenosemicarbazide was formed. On the other hand, the reaction of the hydrazone, which 
had been prepared from 2 and hydrazine, with 1 led quickly to decomposition products.  
 
Table 1: Preparation of Selenadiazines 3 from Isoselenocyanates 1 
 
Based on the results described, we propose the reaction mechanism shown in Scheme 
2 for the formation of 3. We have already demonstrated that isoselenocyanates 1 and 
bifunctional nucleophiles of type 4, bearing an electrophilic group, react to give 2-
iminoselenaheterocycles 6. A likely intermediate is the adduct 5, which undergoes an exo-
trig cyclization [32] to yield five to seven-membered selenaheterocycles [26–28] or 
heterocyclic selones [33][34]. In the present three-component reaction, the nucleophile 
(hydrazine) and the electrophile (2) are separated. Addition of hydrazine to 1 leads to the 
adduct 7, which immediately reacts with the third component 2 to give 8. Finally, an 
intramolecular condensation by elimination of H2O, i.e., the formation of a hydrazone, 
leads to the selenaheterocycles 3. 
 
Scheme 2 
 
In conclusion, we have shown that the three-component reaction of isoselenocyanates 
1, phenacyl halides 2, and hydrazine is a very convenient and useful procedure for the 
preparation of 1,3,4-selenadiazines 3.  
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Experimental Part 
 
1. General. TLC: silica gel 60 F254 plates (0.25 mm; Merck). Column 
chromatography (CC): silica gel 60 (0.040-0.063 mm; Merck). M.p.: Büchi B-540 
apparatus, in capillaries; uncorrected. IR spectra: Perkin-Elmer 1600-FT-IR spectrometer, 
in KBr; absorptions in cm-1. 1H-NMR (300 MHz) and 13C-NMR (75.5 MHz) spectra: 
Bruker ARX-300 instrument, in (D6)DMSO; chemical shifts in ppm, J in Hz; multiplicities 
of C-atoms from DEPT spectra. EI-MS and CI-MS: Finnigan SSQ-700 or MAT-90 
instrument; EI mode: 70 eV; CI mode: NH3 as carrier gas.  
 
2. Starting materials. α-Halogeno acetophenones and hydrazine hydrate are 
commercially available (Fluka). Isoselenocyanates 1a–1e were prepared according to a 
slightly modified procedure of Barton et al. [29] starting from a formamide. Formanilide is 
commercially available (Fluka and Aldrich). N-(4-Chlorophenyl)-, N-(4-bromophenyl)-, N-
(4-methylphenyl)-, and N-(4-methoxyphenyl)formamide were prepared from the respective 
aniline and 95% formic acid. The soln. was heated to reflux for 30 min and evaporated to 
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dryness in vacuo. The residue was dissolved in Et2O and washed with diluted AcOH (5%), 
H2O and aq. NaHCO3 (5%). The aq. layer was extracted with Et2O, the combined org. 
extracts were dried (MgSO4) and evaporated. The crude products were purified by 
recrystallization from EtOH/H2O. 
 
3. General Procedure for the Preparation of Selenadiazines 3a–3f: A 25 ml round-
bottom flask equipped with a magnetic stirrer and condenser was charged with a mixture of 
an isoselenocyanate (1.0 mmol) and a phenacyl halide (1.0 mmol) in CH2Cl2 (20 ml). Then, 
hydrazine hydrate (0.05 ml, 1.0 mmol) was added in one portion, the mixture was stirred 
for 3 to 4 h at r.t. and evaporated to dryness i.v. The crude product was purified by CC on 
silica gel with hexane/AcOEt (100/0 to 50/50) as eluant. 
(Phenyl)(5-phenyl-3,6-dihydro-2H-[1,3,4]selenadiazin-2-yliden)amine (3a). Yield: 
226.3 mg (72%). Yellowish crystals. M.p. 186–188° (AcOEt). IR: 3443m (br.), 3150w, 
3060w, 3034w, 2921m (br.) 1621m, 1580s, 1556vs, 1494m, 1471w, 1404w, 1303w, 1251w, 
1209m, 1172w, 1137w, 1112w, 1075w, 1004w, 899w, 845w, 798w, 766w, 753m, 687m, 
632m. 1H-NMR: 3.95 (s, CH2); 6.95–7.25 (br. m, t-like at 7.12, J = 7.4, 3 arom. H); 7.37 (t-
like, J = 7.7, 2 arom. H); 7.45–7.55 (m, 3 arom. H); 7.91 (d-like, J = 7.7, 2 arom. H); 11.28 
(br. s, NH). 13C-NMR: 15.1 (t, CH2); 123.1 (d, 1 arom. CH); 126.1 (d, 2 arom. CH); 128.4 
(d, 3 arom. CH); 128.5 (d, 2 arom. CH); 129.2 (d, 2 arom. CH); 135.4, 149.0, 155.2 (3s, 2 
arom. C, C(5)); 163.5 (s, C(2)). CI-MS: 318 (19), 317 (17), 316 (100, [M(80Se)+1]+), 315 
(10), 314 (48), 313 (19), 312 (18), 239 (7), 238 (41, [M–Ph]+), 236 (20), 225 (7). Anal. calc. 
for C15H13N3Se (314.25): C 57.33, H 4.17, N 13.37; found: C 57.34, H 4.03, N 13.09. 
Crystals suitable for the X-ray crystal-structure determination were grown from 
CHCl3/MeOH by slow evaporation of the solvent. 
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(4-Bromophenyl)(5-phenyl-3,6-dihydro-2H-[1,3,4]selenadiazin-2-yliden)amine (3b). 
Yield: 267.3 mg (68%). Yellowish crystals. M.p. 179–181° (AcOEt). IR: 3443m (br.), 
3133w, 3056w, 2917m (br), 1623m, 1587vs, 1567s, 1490m, 1472m, 1444m, 1403m, 1297w, 
1276w, 1214s, 1173m, 1105w, 1072m, 1003w, 889m, 841m, 827s, 759s, 693s, 658m, 632w. 
1H-NMR: 3.93 (s, CH2); 6.70–7.00 (br. m, 2 arom. H); 7.45–7.60 (m, 5 arom. H); 7.85–8.00 
(m, 2 arom. H); 11.71 (br. s, NH). 13C-NMR: 15.3 (t, CH2); 121.6 (s, 1 arom. C); 126.2 (d, 
2 arom. CH); 128.5 (d, 3 arom. CH); 129.3 (d, 2 arom. CH); 131.3 (d, 2 arom. CH); 135.3, 
148.0, 154.3 (3s, 2 arom. C, C(5)); 166.2 (s, C(2)). CI-MS: 398 (13), 397 (14), 396 (77), 
395 (21), 394 (100, [M(80Se,79Br)+1]+), 393 (21), 392 (47), 391 (14), 390 (14). Anal. calc. 
for C15H12N3SeBr (393.15): C 45.83, H 3.08, N 10.69; found: C 45.46, H 3.21, N 10.42. 
(4-Chlorophenyl)(5-phenyl-3,6-dihydro-2H-[1,3,4]selenadiazin-2-yliden)amine (3c). 
Yield: 191.8 mg (55%). Yellowish crystals. M.p. 178–180° (AcOEt). IR: 3444m (br.), 
3125w, 3047w, 2908m (br.), 2866m (br.), 1623m, 1584vs, 1568s, 1491s, 1473m, 1444w, 
1403m, 1297w, 1277w, 1214s, 1178w, 1172m, 1107w, 1093m, 1071w, 1003w, 888m, 843w, 
830m, 796w, 760m, 694m, 683w, 662w. 1H-NMR: 3.95 (s, CH2); 6.80–7.05 (br. m, 2 arom. 
H); 7.45 (d-like, J = 8.4, 2 arom. H); 7.50–7.60 (m, 3 arom. H); 7.90–8.05 (m, 2 arom. H); 
11.64 (br. s, NH). 13C-NMR: 15.3 (t, CH2); 126.2 (d, 2 arom. CH); 128.4 (d, 2 arom. CH); 
128.5 (d, 3 arom. CH); 129.3 (s, 2 arom. CH); 135.0, 135.3, 147.5, 155.3 (4s, 3 arom. C, 
C(5)); 163.9 (s, C(2)). CI-MS: 354 (6), 353 (8), 352 (44), 351 (18), 350 (100, 
[M(80Se,35Cl)+1]+), 349 (15), 348 (48), 347 (17), 346 (17). Anal. calc. for C15H12N3SeCl 
(348.69): C 51.67, H 3.47, N 12.05; found: C 51.51, H 3.74, N 11.73. 
(4-Methoxyphenyl)(5-phenyl-3,6-dihydro-2H-[1,3,4]selenadiazin-2-yliden)amine 
(3d). Yield: 229.3 mg (67%). Yellowish crystals. M.p. 132–134° (AcOEt). IR: 3439m (br.), 
3346m, 2912m (br.), 2836w, 1654s, 1638m, 1580vs, 1544s, 1509vs, 1447w, 1282m, 1249s, 
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1211w, 1178w, 1109w, 1077w, 1033w, 1011w, 892w, 826m, 800w, 757w, 713m, 692w. 1H-
NMR: 3.82 (s, MeO); 3.90 (s, CH2); 6.90–7.20 (br. m, d-like at 6.92, J = 8.2, 4 arom. H); 
7.30–7.55 (m, 2 arom. H); 7.75–8.00 (m, 2 arom. H); 11.82 (br. s, NH). 13C-NMR: 15.1 (t, 
CH2); 55.4 (q, MeO); 115.6 (d, 2 arom. CH); 124.2 (d, 2 arom. CH); 128.3 (d, 2 arom. CH); 
129.2 (d, 2 arom. CH); 131.1 (d, 1 arom. CH); 133.9, 147.8, 153.7, 158.4 (4s, 3 arom. C, 
C(5)); 166.1 (s, C(2)). CI-MS: 350 (8), 349 (12), 348 (65), 347 (21), 346 (100, 
[M(80Se)+1]+), 345 (19), 344 (52), 343 (15), 342 (14). Anal. calc. for C16H15N3OSe 
(344.28): C 55.82, H 4.39, N 12.21; found: C 55.95, H 4.67, N 12.23. 
(4-Bromophenyl)[5-(4-bromophenyl)-3,6-dihydro-2H-[1,3,4]selenadiazin-2-
yliden]amine (3e). Yield: 377.6 mg (80%). Yellowish crystals. M.p. 176–178° (AcOEt). 
IR: 3442m (br.), 3155w, 3051w, 2920m (br.), 1626m, 1590vs, 1576s, 1554m, 1485m, 
1407w, 1299w, 1271w, 1209m, 1172m, 1146w, 1101w, 1070m, 1000m, 890w, 828m, 725w, 
707w, 653w, 604w. 1H-NMR: 3.88 (s, CH2); 6.85–7.10 (br. m, 2 arom. H); 7.68 (d-like , J = 
8.2, 2 arom. H); 7.80 (d-like, J = 8.2, 2 arom. H); 7.90–8.00 (m, 2 arom. H); 11.79 (br. s, 
NH). 13C-NMR: 15.0 (t, CH2); 122.8 (s, 2 arom. C); 124.2 (d, 2 arom. CH); 128.1 (d, 2 
arom. CH); 131.3 (d, 2 arom. CH); 131.5 (d, 2 arom. CH); 134.5, 147.2, 155.5 (3s, 2 arom. 
C, C(5)); 162.9 (s, C(2)). CI-MS: 478 (7), 477 (9), 476 (52), 475 (19), 474 (100, 
[M(80Se,81Br,79Br)+1]+), 473 (23), 472 (85, [M(80Se,79Br,79Br)+1]+), 471 (19), 470 (35), 469 
(8), 468 (9). Anal. calc. for C15H11N3SeBr2 (472.05): C 38.17, H 2.35, N 8.90; found: C 
38.01, H 2.54, N 8.60. 
[5-(4-Bromophenyl)-3,6-dihydro-2H-[1,3,4]selenadiazin-2-ylidene](4-
methylphenyl)amine (3f). Yield: 317.5 mg (78%). Yellowish crystals. M.p. 202–204° 
(AcOEt). IR: 3441m (br.), 2919m, 2853m (br.), 1623m, 1583vs, 1554m, 1508w, 1486w, 
1406w, 1269w, 1221m, 1173m, 1075m, 999w, 890w, 826m. 1H-NMR: 2.40 (s, Me); 3.93 (s, 
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CH2); 6.90–7.20 (m, 2 arom. H); 7.24 (d-like, J = 8.1, 2 arom. H); 7.52 (d-like, J = 8.1, 2 
arom. H); 7.66 (d-like, J = 8.1, 2 arom. H); 11.50 (br. s, NH). 13C-NMR: 14.8 (t, CH2); 20.3 
(q, Me); 121.6 (s, 1 arom. C); 122.6 (d, 2 arom. CH); 128.0 (d, 2 arom. CH); 129.0 (d, 2 
arom. CH); 131.4 (d, 2 arom. CH); 134.7, 145.6, 155.0 (3s, 3 arom. C, C(5)); 163.2 (C(2)). 
CI-MS: 412 (13), 411 (15), 410 (77), 409 (33), 408 (100, [M(80Se,79Br)+1]+), 407 (40), 406 
(50), 405 (23), 404 (17). Anal. calc. for C16H14N3SeBr (407.07): C 47.20, H 3.47, N 10.32; 
found: C 46.72, H 3.51, N 10.15. 
X-Ray Crystal-Structure Determination of 3a (see Table and Figure)3). All 
measurements were made on a Nonius KappaCCD diffractometer [35] using graphite-
monochromated MoKα radiation (λ 0.71073 Å) and an Oxford Cryosystems Cryostream 
700 cooler. Data reduction was performed with HKL Denzo and Scalepack [36]. The 
intensities were corrected for Lorentz and polarization effects, and an absorption correction 
based on the multi-scan method [37] was applied. Equivalent reflections were merged. Data 
collection and refinement parameters are given in the Table, and a view of the molecule is 
shown in the Figure. The structure was solved by direct methods using SIR92 [38], which 
revealed the positions of all non-H-atoms. The non-H-atoms were refined anisotropically. 
The amine H-atom was placed in the position indicated by a difference electron density 
map and its position was allowed to refine together with an isotropic displacement 
parameter. All of the remaining H-atoms were placed in geometrically calculated positions 
and refined using a riding model where each H-atom was assigned a fixed isotropic 
                                                          
3) CCDC-601303 contains the supplementary crystallographic data for this paper. These 
data can be obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
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displacement parameter with a value equal to 1.2Ueq of its parent C-atom. Refinement of 
the structure was carried out on F2 using full-matrix least-squares procedures, which 
minimized the function Σw(Fo
2-Fc
2)2.  A correction for secondary extinction was applied. 
One reflection, whose intensity was considered to be an extreme outlier, was  omitted from 
the final refinement. Neutral atom scattering factors for non-H-atoms were taken from 
[39a], and the scattering factors for H-atoms were taken from [40].  Anomalous dispersion 
effects were included in Fc [41]; the values for ƒ’ and ƒ” were those of [39b]. The values of 
the mass attenuation coefficients are those of [39c]. All calculations were performed using 
the SHELXL97 [42] program. 
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Table 1. Preparation of Selenadiazines 3 from Isoselenocyanates 1 
 
Entry 1 R1  2 R2                     Selenadiazines 3 Yield (%) 
 
1 
 
a 
 
Ph 
 
a 
 
Ph 
 
a Se
NHN
N
 
 
72 
 
2 
 
b 
 
4-BrC6H4 
 
a 
 
Ph 
 
b Se
NHN
N
Br  
 
68 
 
3 
 
c 
 
4-ClC6H4 
 
a 
 
Ph 
 
c Se
NHN
N
Cl  
 
55 
 
4 
 
d 
 
4-MeOC6H4 
 
 
a 
 
Ph 
 
 
d Se
NHN
N
MeO  
 
67 
 
5 
 
b 
 
4-BrC6H4 
 
b 
 
4-BrC6H4 
 
e Se
NHN
N Br
Br  
 
80 
 
6 
 
e 
 
4-MeC6H4 
 
b 
 
4-BrC6H4 
 
f Se
NHN
N
H3C
Br
 
 
78 
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Table 2.  Crystallographic Data of Compound 3a 
 
Crystallized from  CHCl3/MeOH 
Empirical formula  C15H13N3Se 
Formula weight [g mol-1]  314.19 
Crystal color, habit  pale-yellow, prism 
Crystal dimensions [mm]  0.18 × 0.23 × 0.28 
Temperature [K]  160(1) 
Crystal system  monoclinic 
Space group  P21/n  
Z  4 
Reflections for cell determination  27519 
2θ range for cell determination [°]  4 – 60 
Unit cell parameters a [Å] 10.5899(2) 
  b [Å]  8.7839(1) 
  c [Å]  15.2309(3) 
  β [°]  110.2058(9) 
  V [Å3]  1329.60(4) 
Dx [g cm-3]  1.569 
µ(MoKα) [mm-1]  2.811 
Scan type  φ and ω 
2θ (max) [°]  60 
Transmission factors (min; max)  0.510; 0.623 
Total reflections measured  37327 
Symmetry independent reflections  3883 
Reflections with I > 2σ (I)  3316 
Reflections used in refinement  3882 
Parameters refined  177 
Final R(F)  [I > 2σ (I) reflections]  0.0297 
  wR(F2)  (all data)  0.0750 
Weights: w = [σ 2(Fo2) + (0.0359P)2 + 0.9122P]-1 where P = (Fo2 + 2Fc2) / 3 
Goodness of fit  1.033 
Secondary extinction coefficient  0.0036(8) 
Final ∆ max /σ  0.002 
∆ρ (max; min) [e Å-3]  0.64; -0.50 
 
 
 
 
